30532-36-6

Usage

Uses

Used in Pharmaceutical Industry:
4-Pyridinepropanamine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of antihistamines and bronchodilators. Its presence in these medications aids in the treatment of allergies and respiratory conditions, respectively.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Pyridinepropanamine is utilized as an intermediate in the production of agrochemicals, contributing to the development of compounds that protect crops and enhance agricultural productivity.
Used as a Corrosion Inhibitor:
4-Pyridinepropanamine is employed as a corrosion inhibitor in various industrial applications, where it helps to prevent the degradation of materials and extend the lifespan of equipment and structures.
Used as a Precursor in Chemical Synthesis:
4-Pyridinepropanamine also serves as a precursor to other chemical compounds, enabling the creation of a wide range of products across different industries, from specialty chemicals to advanced materials.

Upstream product

• 2629-72-3 4-(3-Hydroxypropyl)pyridine 
• 84200-07-7 3-(pyridin-4-yl)-propionamide 
• 5264-02-8 3-(4-pyridyl)-1-chloropropane 
• 84200-08-8 N-[3-(pyridin-4-yl)propyl]phthalimide 

Downstream Products

• 120554-87-2 (E)-5,5-bis(4-methoxyphenyl)-N-[3-(4-pyridinyl) propyl]-2,4-pentadienamide 
• 885268-87-1 4-(3-N-tert-butoxycarbonylaminopropyl)piperidine 
• 1555938-69-6 N₁,N₂-bis(benzyloxycarbonyl)-N₃-[3-(pyridin-4-yl)propyl]guanidine 
• 1192559-72-0 1-cyano-2-phenyl-3-[3-(pyridin-4-yl)propyl]isourea 
• 362709-28-2 N-[3-(4-Pyridinyl)propyl]-3-(3,4,8,9-tetrahydro-6-methoxy-3,3,8,8-tetramethylfuro[2,3-h]isoquinolin-1-yl)benzamide 
• 145301-48-0 BIBN 99 

Relevant academic research and scientific papers

Synthesis, SAR and selectivity of 2-acyl- and 2-cyano-1-hetarylalkyl- guanidines at the four histamine receptor subtypes: A bioisosteric approach

In the search for potential bioisosteres of the 4-imidazolyl ring in acylguanidines (e.g. UR-AK24), known to possess affinity to several histamine receptor subtypes (HxR, x = 1-4), and cyanoguanidine-type H 4R agonists (e.g. UR-PI376

THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS

Provided herein are novel substituted thieno[3,2-d]pyrimidine-6-carboxamide sirtuin inhibitors and methods of use thereof. The sirtuin inhibitors may be used for inhibiting a sirtuin-mediated biological process, and, e.g. for treating and/or preventing diseases and disorders including, but not limited to cancer, neurodegenerative disease and inflammation. Also provided herein are pharmaceutical compositions comprising these sirtuin inhibitors and compositions comprising a sirtuin inhibitor in combination with another therapeutic agent.

Discovery of thieno[3,2-d ]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3

The sirtuins SIRT1, SIRT2, and SIRT3 are NAD+ dependent deacetylases that are considered potential targets for metabolic, inflammatory, oncologic, and neurodegenerative disorders. Encoded library technology (ELT) was used to affinity screen a 1

Syntheses and biological activities of structurally stiff rhodacyanines as novel antimalarial candiadates

New classes of rhodacyanine as structurally stiff derivatives were designed and synthesized. The synthetic compounds were evaluated the antimalarial activity and cytotoxicity in vitro.

INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS

The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptor.

PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS

The invention provides compounds of formula (I) prodrugs thereof, and the pharmaceutically acceptable salts of the compounds or prodrugs, wherein n, X, and Y are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereo

Tnf-alpha production inhibitors

A purpose of the present invention is to provide TNF-α production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. Novel compounds having the structure represented by the general formula [1] or salts ther

Bicyclic fibrinogen antagonists

This invention relates to compounds of the formulae: wherein A1is O, S, N—R1or CHR1; A4is N—R4or CHR4; R2is a sidechain containing an acid or ester group; R1, R4and R5are substituents such as H, alkyl and aryl alkyl, and R6is a sidechain containing a nitrogen group; and pharmaceutically acceptable salts thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.

Polymer bound iminodicarbonate: A new ammonia equivalent for solid-phase synthesis of primary amines

A polymer bound iminodicarbonate has been designed and its use in solid-phase synthesis of primary amines is reported. (C) Elsevier Science Ltd.

Fibrinogen receptor antagonists

Fibrinogen receptor antagonists having the structure, for example, of STR1 for example STR2